Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials
In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseases Shots: Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
March 1, 2022
PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosis Shots: The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & Taiwan Zai Lab gets exclusive rights to develop &…
February 28, 2022
Viewpoints_Senior Editor
PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy
In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasia Shots: The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 2022
Viewpoints_Tania Small
PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program
In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma community Shots: The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the community A grant of…
February 23, 2022
PharmaShots Interview Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA’s Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
In an interview with PharmaShots, Todd Fox, Global Medical Franchise Head, Immunology Hepatology and Dermatology at Novartis shares his views on Cosentyx in P-III (JUNIPERA) study for the treatment of enthesitis-related arthritis and psoriatic arthritis Shots: The approval is based on the P-III (JUNIPERA) study to evaluate Cosentyx (75/150mg) vs PBO in 86 children & adolescents aged 2 to 18yrs. with ERA…
February 22, 2022
PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgery Shots: The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 2022
PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation
In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete. Additional programs using anti-TNF soon to…
February 15, 2022
PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 2022
Viewpoints_Philip M. Brown
PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM
In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque Psoriasis Shots: The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 2022
Viewpoints_Laura Dix
PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions
In an interview with PharmaShots, Laura Dix, a Managing Director in Accenture’s Life Sciences Strategy and Consulting practice shares her views on the new research & provides more useful, data-driven information to HCPs  Shots: The company unveiled new research, titled The “New” Rules of Engagement & which have increased their relevance during COVID-19 through more valuable and meaningful interactions with…
February 2, 2022
Load more